Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
NFL
U.S.
2024 Election
Local
World
Science
Technology
AI
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
HIV Breakthrough as New Injection 89% More Effective Than PrEP
"PrEP reduces the risk of getting HIV from sex by about 99 percent when taken as prescribed. Although there is less information about how effective PrEP pills are among people who inject drugs, we know that PrEP pills reduce the risk of getting HIV by at least 74 percent when taken as prescribed," the CDC says.
Twice-Yearly Injection 96% Effective in Preventing HIV Infection
A twice-yearly injection of Sunlenca (lenacapavir) reduces the risk of HIV infection by 96%, which is significantly more effective than oral pre-exposure prophylaxis (PrEP) using pills like Truvada, researchers report in the New England Journal of Medicine.
Gilead’s twice-yearly lenacapavir shows promise in HIV prevention trial
The Phase III Purpose 2 trial compared the safety and efficacy of twice-yearly subcutaneous lenacapavir for pre-exposure prophylaxis (PrEP) against once-daily oral Truvada.
Twice-Yearly Injection Reduces Risk of HIV Infection by 96%
For oral medications that prevent new HIV infection to be effective, the patient must take certain actions, including attending doctor's visits every three months and—most importantly—cons
HIV infections can be prevented – why some people act to protect themselves, and others don’t
People are at the heart of the HIV pandemic, so it’s important to understand how they make protection decisions.
New HIV prevention injection offers 96% protection
For oral medications that prevent new HIV infection to be effective, the patient must take certain actions, including attending doctor's visits every three months and – most importantly – consistency.
5h
on MSN
We are closer than ever to a future without HIV – our leaders must rise to the occasion
Almost half of these new infections were among young women and girls, bringing the global total number of people living with ...
EurekAlert!
1d
Clinical trial at Emory University reveals twice-yearly injection to be 96% effective in HIV prevention
These daily oral antiretrovirals, more commonly referred to as PrEP (
pre-exposure
prophylaxis
), such as Truvada®, are ...
The Kenya Times on MSN
1d
Bill Gates Opens Up on Finding Lifetime HIV Vaccine
U.S. philanthropist and entrepreneur Bill Gates has opened up about the search for a lifetime HIV vaccine, rather than one ...
Too Old to Operate
1d
Q&A: Addressing Barriers to Long-Acting Injectable PrEP for Transgender Women
Research shows many transgender women in the U.S. express interest in long-acting injectable PrEP but face barriers to ...
15h
Gilead announces PURPOSE 2 trial data published in NEJM
Gilead (GILD) announced The New England Journal of Medicine, or NEJM, published the full results from the company’s pivotal Phase 3 PURPOSE 2 ...
CSR Wire
23h
Gilead Sciences: Designing Inclusive Clinical Trials in an Effort To Upend the HIV Epidemic
Lead PURPOSE researcher Moupali Das, Vice President, Clinical Development, HIV Prevention & Pediatrics, designed the PURPOSE ...
ETX Daily Up on MSN
2d
Fewest new HIV cases since late 1980s: UNAIDS report
UNAIDS report Fewer people contracted HIV last year than at any point since the rise of the disease in the late 1980s, the United Nations said Tuesday, warning that this decline was still far too slow ...
Medscape
3d
Family Doctors Can Intervene to Treat and Prevent STIs
Many family physicians may be unaware of doxy PEP as a means of avoiding STIs. “Doxy PEP is an incredible tool that can be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback